Ken Griffin’s Denali Therapeutics DNLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.48M | Sell |
181,417
-597,731
| -77% | -$11.9M | ﹤0.01% | 4969 |
|
|
2025
Q4 | $12.9M | Buy |
779,148
+90,924
| +13% | +$1.53M | ﹤0.01% | 2915 |
|
|
2025
Q3 | $9.99M | Sell |
688,224
-560,729
| -45% | -$8.06M | ﹤0.01% | 3271 |
|
|
2025
Q2 | $17.5M | Buy |
1,248,953
+79,270
| +7% | +$1.12M | ﹤0.01% | 2305 |
|
|
2025
Q1 | $15.9M | Buy |
1,169,683
+339,772
| +41% | +$6.51M | ﹤0.01% | 2294 |
|
|
2024
Q4 | $16.9M | Buy |
829,911
+52,631
| +7% | +$1.35M | ﹤0.01% | 2351 |
|
|
2024
Q3 | $22.6M | Sell |
777,280
-441,418
| -36% | -$10.9M | ﹤0.01% | 1915 |
|
|
2024
Q2 | $28.3M | Sell |
1,218,698
-146,330
| -11% | -$2.81M | 0.01% | 1661 |
|
|
2024
Q1 | $28M | Buy |
1,365,028
+1,296,918
| +1,904% | +$24.4M | 0.01% | 1734 |
|
|
2023
Q4 | $1.46M | Buy |
68,110
+6,205
| +10% | +$123K | ﹤0.01% | 5941 |
|
|
2023
Q3 | $1.28M | Buy |
61,905
+5,802
| +10% | +$147K | ﹤0.01% | 6080 |
|
|
2023
Q2 | $1.66M | Sell |
56,103
-1,318,222
| -96% | -$37.1M | ﹤0.01% | 5494 |
|
|
2023
Q1 | $31.7M | Buy |
1,374,325
+1,339,712
| +3,871% | +$36.9M | 0.01% | 1487 |
|
|
2022
Q4 | $963K | Sell |
34,613
-28,924
| -46% | -$861K | ﹤0.01% | 6896 |
|
|
2022
Q3 | $1.95M | Sell |
63,537
-242,465
| -79% | -$7.88M | ﹤0.01% | 5636 |
|
|
2022
Q2 | $9.01M | Sell |
306,002
-445,601
| -59% | -$11.7M | ﹤0.01% | 2829 |
|
|
2022
Q1 | $24.2M | Buy |
751,603
+265,920
| +55% | +$9.15M | 0.01% | 1768 |
|
|
2021
Q4 | $21.7M | Buy |
485,683
+422,672
| +671% | +$20M | ﹤0.01% | 1922 |
|
|
2021
Q3 | $3.18M | Buy |
+63,011
| New | +$3.55M | ﹤0.01% | 5234 |
|
|
2021
Q2 | – | Sell |
-240,784
| Closed | -$14.9M | – | 13799 |
|
|
2021
Q1 | $13.7M | Buy |
240,784
+235,671
| +4,609% | +$15.8M | ﹤0.01% | 2503 |
|
|
2020
Q4 | $428K | Sell |
5,113
-213,024
| -98% | -$12.9M | ﹤0.01% | 8422 |
|
|
2020
Q3 | $7.82M | Buy |
218,137
+107,572
| +97% | +$3.24M | ﹤0.01% | 2592 |
|
|
2020
Q2 | $2.67M | Buy |
110,565
+38,213
| +53% | +$898K | ﹤0.01% | 4055 |
|
|
2020
Q1 | $1.27M | Buy |
72,352
+18,766
| +35% | +$391K | ﹤0.01% | 4916 |
|
|
2019
Q4 | $933K | Sell |
53,586
-34,823
| -39% | -$580K | ﹤0.01% | 5717 |
|
|
2019
Q3 | $1.35M | Sell |
88,409
-106,467
| -55% | -$2.03M | ﹤0.01% | 5098 |
|
|
2019
Q2 | $4.04M | Buy |
194,876
+167,111
| +602% | +$3.74M | ﹤0.01% | 3409 |
|
|
2019
Q1 | $645K | Buy |
+27,765
| New | +$581K | ﹤0.01% | 6358 |
|
|
2018
Q3 | – | Sell |
-49,421
| Closed | -$753K | – | 9286 |
|
|
2018
Q2 | $753K | Buy |
+49,421
| New | +$931K | ﹤0.01% | 5702 |
|
Other funds holding DNLI
VCM
VPM
Ken Griffin's DNLI Position: Q1 2026 in Review
Ken Griffin reduced its Denali Therapeutics (DNLI) stake by 77% in Q1 2026, selling an estimated $11.9M and leaving 181,417 shares worth $3.48M. The position accounts for ﹤0.01% of the portfolio, ranked #4969.
Ken Griffin first reported a position in DNLI in Q2 2018 and has held it in 29 quarters since. The position peaked at $31.7M in Q1 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.
- Ken Griffin held 181,417 shares of Denali Therapeutics worth $3.48M as of Q1 2026.
- Ken Griffin sold 597,731 Denali Therapeutics shares in Q1 2026, an estimated $11.9M.
- Denali Therapeutics made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #4969 holding.
- Ken Griffin first reported a position in Denali Therapeutics in Q2 2018 and has held it in 29 quarters since.
- Ken Griffin's Denali Therapeutics position peaked at $31.7M in Q1 2023.
- 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.